Ebglyss Pen (Lebrikizumab-Lbkz) Patent Expiration, LOE Window & CMS Spending
Ebglyss Pen (Lebrikizumab-Lbkz) by Eli Lilly: Biologic BLA (Purple Book Regime), 0 AB generics, $4.0M 2024 CMS Part D & Medicaid spend, and $3,500 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | B761306 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $4.0M |
| 2024 Medicare Part D Spend | $2.9M |
| 2024 Medicaid Spend | $1.1M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,500 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.